Towards Healthcare
Drug-Induced Dyskinesia Market Increases to USD 436.2 Mn in 2025

Drug-Induced Dyskinesia Market Innovation Driving Growth

According to forecasts, the global drug-induced dyskinesia market will grow from USD 418 million in 2024 to USD 627.5 million by 2034, with an expected CAGR of 4.34%. The market is growing due to the rising prevalence of Parkinsons disease and increased long-term use of dopaminergic therapies. North America dominated the market due to the rising development of novel therapeutics.

Content

  • Insight Code: 6110
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The drug-induced dyskinesia market holds a valuation of USD 436.2 million as of 2025, and will expand to USD 627.5 million by 2034, achieving a CAGR of 4.34% between 2024 and 2034.

North America is leading the drug-induced dyskinesia market due to its high prevalence of Parkinsons disease, strong adoption of innovative therapies, presence of leading pharmaceutical companies, well-established neurology care infrastructure, and supportive reimbursement frameworks that ensure access to advanced treatments.

By Drug Class, By Indication, By Route of Administration, By End User, By Region

Global market growth is being boosted by the increasing incidence of Parkinsons disease and tardive dyskinesia, the rising adoption of novel VMAT2 inhibitors, strong R&D pipelines for advanced therapies, government and NGO-backed awareness campaigns, and increasing investments in Asia-Pacific and Latin America as emerging treatment markets.

FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), CDSCO (India), National Institute of Neurological Disorders and Stroke (NINDS), Michael J. Fox Foundation for Parkinsons Research, World Health Organization (WHO), Parkinsons Foundation, National Alliance on Mental Illness (NAMI).
Any Questions